Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial

• Published in: Schizophrenia research 2023-04, Vol.254, p.92-98
• Main Authors: Karbalaee, Monire, Jameie, Melika, Amanollahi, Mobina, TaghaviZanjani, Fateme, Parsaei, Mohammadamin, Basti, Fatemeh A., Mokhtari, Saba, Moradi, Kamyar, Ardakani, Mohammad-Reza Khodaei, Akhondzadeh, Shahin
• Format: Article
• Language: English
• Subjects: Antipsychotic agents; Antipsychotic Agents - adverse effects; Clinical trial; Double-Blind Method; Drug Therapy, Combination; Fingolimod; Fingolimod Hydrochloride - adverse effects; Humans; Risperidone - therapeutic use; Schizophrenia; Schizophrenia - etiology; Treatment Outcome; White matter
• ISSN: 0920-9964; 1573-2509
• DOI: 10.1016/j.schres.2023.02.020

Studies have suggested that fingolimod, a sphingosine-1-phosphate receptor modulator, exerts neuroprotective and anti-inflammatory effects. Although fingolimod is approved for the treatment of relapsing-remitting multiple sclerosis, limited studies have investigated its effects in patients with schizophrenia. This study investigated the efficacy and safety of fingolimod adjuvant to risperidone in schizophrenia treatment. This eight-week, randomized, double-blinded, placebo-controlled trial included 80 (clinical trials registry code: IRCT20090117001556N137) patients with chronic schizophrenia. Participants were assigned to two equal arms and received risperidone plus either fingolimod (0.5 mg/day) or a matched placebo. The positive and negative symptom scale (PANSS) was used to measure and compare the effectiveness of treatment strategies at baseline and weeks 2, 4, 6, and 8. Treatment side effects were also compared. Seventy participants completed the trial (35 in each arm). The baseline characteristics of the groups were comparable (P-value > 0.05). There were significant time-treatment interaction effects on negative symptoms (P-value = 0.003), general symptoms (P-value = 0.037), and the PANSS total score (P-value = 0.035), suggesting greater improvement in symptoms following the fingolimod adjuvant therapy. In contrast, the longitudinal changes in positive and depressive symptoms were similar between the groups (P-values > 0.05). Regarding the safety of treatments, there were no differences in extrapyramidal symptoms [assessed by the extrapyramidal symptom rating scale (ESRS)] or frequency of other complications between the fingolimod and the placebo groups (P-values > 0.05). This study indicated that fingolimod is a safe and effective adjuvant agent for schizophrenia treatment. However, further clinical trials are required to suggest extensive clinical application.